河北医科大学学报 ›› 2023, Vol. 44 ›› Issue (9): 1017-1021.doi: 10.3969/j.issn.1007-3205.2023.09.005

• • 上一篇    下一篇

佐匹克隆与氯硝西泮治疗精神分裂症伴睡眠障碍的效果比较

  

  1. 1.湖北省武汉市优抚医院睡眠心理科,湖北 武汉 430000;2.湖北省武汉市优抚医院中西结合精神病科,
    湖北 武汉 430000;3.湖北省武汉市优抚医院精神科,湖北 武汉430000
  • 出版日期:2023-09-25 发布日期:2023-10-12
  • 作者简介:吴江(1975-),男,湖北保康人,湖北省武汉市优抚医院主任医师,医学硕士,从事精神病与精神卫生研究。
  • 基金资助:
    湖北省卫生健康委员会项目(WJ2021M036)

Comparison of effects of zopiclone and clonazepam in the treatment of schizophrenia and sleep disorders

  1. 1.Department of Sleep Psychology, Wuhan Youfu Hospital,  Hubei Province, Wuhan 430000, China; 
    2.Department of Integrated Traditional Chinese and Western Psychiatry, Wuhan Youfu Hospital, 
    Hubei Province, Wuhan 430000, China; 3.Department of Psychiatry, Wuhan Youfu Hospital , 
    Hubei Province, Wuhan 430000, China

  • Online:2023-09-25 Published:2023-10-12

摘要: 目的  比较佐匹克隆与氯硝西泮治疗精神分裂症伴睡眠障碍的临床效果。
方法  选取精神分裂症伴睡眠障碍患者94例为研究对象,均给予常规治疗。采用随机数字表法将患者分为佐匹克隆组、氯硝西泮组,佐匹克隆组给予佐匹克隆治疗,氯硝西泮组给予氯硝西泮治疗。比较2组治疗效果、睡眠脑电图参数及神经电生理指标,分别采用阳性和阴性症状量表评分表(positive and negative syndrome,PANSS)及重复性成套神经心理状态测验(repeatable battery for the assessment of neuropsychological status,RBANS)评价患者治疗前及治疗后精神分裂症症状严重程度及认知功能,并统计患者治疗期间药物相关不良反应发生情况。
结果  2组治疗总有效率比较差异无统计学意义(P>0.05);2组治疗后PANSS评分各项得分差异无统计学意义(P>0.05);佐匹克隆组治疗后P300、N2-P3波幅大于氯硝西泮组,睡眠脑电图S3期时间长于氯硝西泮组(P<0.05);佐匹克隆组治疗后RBANS评分中注意力、延时记忆得分高于氯硝西泮组(P<0.05);氯硝西泮组嗜睡及肌强直发生率高于佐匹克隆组(P<0.05)。
结论  相比于氯硝西泮,佐匹克隆治疗精神分裂症伴睡眠障碍,可有效延长睡眠脑电图S3期时间,改善脑神经电生理状况,并可提高患者认知功能,降低不良反应发生率,但两种药物对患者精神状况的影响相当。


关键词: 精神分裂症, 睡眠障碍, 佐匹克隆, 氯硝西泮

Abstract: Objective  To compare the clinical effects of zopiclone and clonazepam in the treatment of schizophrenia and sleep disorders. 
Methods  In total, 94 patients with schizophrenia complicated by sleep disorders were selected as the research subjects, and they were all given conventional treatment. The patients were divided into zopiclone group and clonazepam group by the random number table method. Zopiclone group and clonazepam group were treated with zopiclone and clonazepam respectively. The therapeutic efficacy, sleep electroencephalogram parameters and nerve electrophysiological indicators were compared between two groups, and positive and negative symptom scale (PANSS) and repeatable battery for the assessment of neuropsychological status (RBANS) were used to evaluate the severity of schizophrenia symptoms and cognitive function before and after treatment. The occurrence of drug-related adverse reactions during treatment were statistically analyzed. 
Results  There was no significant difference in the total effective rate between two groups (P>0.05) as well as in scores of items of PANSS between two groups after treatment (P>0.05). After treatment, the amplitudes of P300 and N2-P3 in zopiclone group were greater than those in clonazepam group, and the duration of S3 phase of sleep electroencephalogram was longer than that in clonazepam group (P<0.05). The RBANS scores of attention and delayed memory in zopiclone group after treatment were higher than those in clonazepam group (P<0.05). The incidence rates of somnolence and myotonia were higher in clonazepam group than in zopiclone group (P<0.05). 
Conclusion  In the treatment of schizophrenia and sleep disorders, zopiclone, as compared with clonazepam, can more effectively prolong the S3 phase of sleep electroencephalogram, improve the electrophysiological status of brain nerve, enhance the cognitive function, and reduce the incidence rates of adverse reactions, but both drugs have similar effects on mental status of patients. 


Key words: schizophrenia, sleep disorders, zopiclone, clonazepam